Tumor-induced osteomalacia: An overview

BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM(2024)

引用 0|浏览4
暂无评分
摘要
Tumor-induced osteomalacia (TIO) is rare paraneoplastic syndrome of hypophosphatemic osteomalacia, caused by phosphaturic factors secreted by small mesenchymal origin tumors with distinct pathological features, called 'phosphaturic mesenchymal tumors'. FGF23 is the most well-characterized of the phosphaturic factors. Tumors are often small and located anywhere in the body from head to toe, which makes the localisation challenging. Functional imaging by somatostatin receptor-based PET imaging is the first line investigation, which should be followed with CT or MRI based anatomical imaging. Once localised, complete surgical excision is the treatment of choice, which brings dramatic resolution of symptoms. Medical management in the form of phosphate and active vitamin D supplements is given as a bridge to surgical management or in inoperable/non-localised patients. This review provides an overview of the epidemiology, pathophysiology, pathology, clinical features, diagnosis, and treatment of TIO, including the recent advances and directions for future research in this field. (c) 2023 Elsevier Ltd. All rights reserved.
更多
查看译文
关键词
tumour induced osteomalacia,oncogenic osteomalacia,fibroblast growth factor 23 (FGF23),phosphaturic mesenchymal tumour-mixed,connective tissue (PMT MCT)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要